abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página no está disponible en Español y está siendo mostrada en English

Artículo

22 Feb 2007

Autor:
Globe and Mail [Canada]

CSR: Pharmaceutical

[Results of Globe & Mail / Jantzi Research survey of pharmaceutical sector. Compares social & environmental performance of the following companies, listed from highest score to lowest: Sanofi Aventis, Novartis, Novo Nordisk, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck, Biovail, Roche, Pfizer.] Controversies swirl around product safety, questionable marketing practices, the high cost of drugs and patent protection issues that leave one-third of the world's population without regular access to essential medicines. The environmental impact of pharmaceutical companies...includes chemical waste and toxic emissions...Some...companies, such as Novartis and Pfizer, have...joint...initiatives aimed at treating infectious diseases such as HIV/AIDS, malaria and tuberculosis, and others are lowering prices and extending product licences in developing countries.

Línea del tiempo